Low Sinusoidal Obstruction Syndrome Rate Seen with InO + Defibrotide Before HSCT

https://www.medscape.com/viewarticle/low-sinusoidal-obstruction-syndrome-rate-seen-ino-2026a10012tt?src= Children with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) treated with inotuzumab ozogamicin (InO) before hematopoietic stem cell transplant (HSCT) had sinusoidal obstruction syndrome (SOS) rates similar to those without prior InO when defibrotide prophylaxis was used. Among patients who received InO and defibrotide prophylaxis, 15% developed SOS, compared with 12% in the non-InO group.